Viridian Therapeutics Inc
VRDN
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.5B
Close$
$-11.56
166.9% downside
Current Fair Value
166.9% downsideOvervalued by 166.9% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.50 Billion |
|---|---|
| Enterprise Value | $1.37 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-3.32 |
| Beta | 0.9 |
| Outstanding Shares | 102,211,657 |
Return
| Return on Equity | -56.70% |
|---|---|
| Return on Assets | -45.70% |
| Return on Invested Capital | -50.23% |
Valuation & Multiples
| P/E Ratio | -4.71 |
|---|---|
| PEG | -22.77 |
| Price to Sales | - |
| Price to Book Ratio | 2.88 |
| Enterprise Value to Revenue | 19.34 |
| Enterprise Value to EBIT | -3.7 |
| Enterprise Value to Net Income | -4 |
| Total Debt to Enterprise | 0.04 |
| Debt to Equity | 0.08 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 12, 2026
EPS Estimate
$-1.04
Average shareholder expectationRevenue Estimate
$21,182
Average shareholder expectationNext Earnings Call
Expected Date
August 5, 2026
EPS Estimate
$-1.03
Average shareholder expectationRevenue Estimate
$2.11 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 1.4619▲ 92.27% |
|---|---|
| Total Calls | 307,200▲ 607.83% |
| Total Puts | 449,100▲ 1819.23% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 132.52%▲ 0.68% |
|---|---|
| Total Invested | $2.21B▼ 34.05% |
| Investors Holding | 230▼ 3.00% |
ESG Score
No data
About Viridian Therapeutics Inc
27 employees
CEO: William Marshall Viridian Therapeutics is a biotechnology company advancing new treatments for patients suffering from serious diseases but underserved by today’s therapies. Viridian’s most advanced program, VRDN-001, is a clinical-stage anti-IGF-1R mono...